US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by LEO Pharma

< Previous 1 2 3 Next >
News headline image
LEO Pharma presents new data on delgocitinib cream at EADV 2026 highlighting real-world outcomes in adults and new adolescent data in Chronic Hand Eczema (CHE)
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma to Showcase Its Broadest Ever Scientific Program at EADV 2026
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma Receives Positive CHMP Opinion Recommending Anzupgo® (delgocitinib) Cream for Adolescents With Moderate to Severe Chronic Hand Eczema in the EU
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma Announces FDA Acceptance of Dersimelagon NDA with Priority Review and Closes Acquisition from Tanabe Pharma
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma Inc. (Canada) Finalizes Letter of Intent with pCPA for Anzupgo® (delgocitinib cream) for Chronic Hand Eczema
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma delivers 10% revenue growth at CER and strengthens late-stage pipeline
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma Further Strengthens Late-Stage Pipeline With the Acquisition of Dersimelagon
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma Announces Key Results of Phase 2 TRAPEDS-1 Trial Evaluating Pharmacokinetics and Safety of Tralokinumab in Children With Moderate-to-Severe Atopic Dermatitis
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma to Showcase New Data Highlighting the Burden and Unmet Needs in Chronic Hand Eczema at ESCD 2026 in Copenhagen
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma Delivers 9% Revenue Growth at CER in Q1 2026 and Strengthens Innovation Pipeline
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma Bolsters Rare Skin Disease Focus Through Acquisition of Replay Gene Therapy Platform
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma expands its psoriasis portfolio in China with NMPA approval of Enstilar®
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma Announces FDA Acceptance of Supplemental NDA for ANZUPGO® (delgocitinib) Cream for the Treatment of Chronic Hand Eczema in Children Aged 12-17
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma Presents New 12-Month Real-World Data for Tralokinumab at AAD 2026
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma Announces New Long-Term Data for SPEVIGO® (spesolimab-sbzo) Injection in Adults with Generalized Pustular Psoriasis at AAD 2026
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma to Present 17 Scientific Abstracts at AAD 2026 Highlighting Real‑World Evidence, Long‑Term Outcomes and Patient Experience Across Multiple Dermatological Conditions
From LEO Pharma
Via Business Wire
News headline image
“It’s GO time”: LEO Pharma launches Direct-to-Consumer campaign to raise awareness of Chronic Hand Eczema
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma Delivers 10% Revenue Growth in 2025 and More Than Doubles Adjusted EBITDA Margin
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma Presents Twenty-Three Posters at Maui Derm Hawaii 2026, Demonstrating Continued Commitment to Scientific Innovation in Medical Dermatology
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma advances Anzupgo® (delgocitinib) cream to phase 3 trial in lichen sclerosus (LS)
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma to Present at the 44th Annual J.P. Morgan Healthcare Conference
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma Appoints Marika Murto to Lead Global Product Strategy
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma Submits Adolescent Label Expansion Application for Anzupgo® to EMA
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma Announces Positive Topline 32-Week Key Results in ADHAND Trial
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma Delivers 8% Revenue Growth at CER in 9M 2025 and Updates Full-Year Outlook
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma Announces NICE Recommendation of Reimbursement in England and Wales
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma Strengthens Leadership in Medical Dermatology with the Appointment of Sophie Lamle as Chief Development Officer
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma Reinforces Leadership in Medical Dermatology with New Data from Across Its Portfolio at 2025 Fall Clinical Dermatology Conference
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma Closes Deal for Spevigo®
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma Presents Late-Breaking Data at EADV 2025 Showing Week 16 Tralokinumab Response Predicts Long-Term Response in Moderate-to-Severe Atopic Dermatitis
From LEO Pharma
Via Business Wire
< Previous 1 2 3 Next >